Home › Compare › AMIN vs JNJ

AMIN vs JNJ: Dividend Comparison 2026

AMIN yields 500000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMIN wins by $252475121624236192.00M in total portfolio value
10 years
AMIN
AMIN
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$252475121624236192.00M
Annual income
$179,970,099,914,313,700,000,000.00
Full AMIN calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AMIN vs JNJ

📍 AMIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMINJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMIN + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AMIN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMIN
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$152,974,584,927,166,630,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AMIN beats the other by $152,974,584,927,166,630,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMIN + JNJ for your $10,000?

AMIN: 50%JNJ: 50%
100% JNJ50/50100% AMIN
Portfolio after 10yr
$126237560812118096.00M
Annual income
$89,985,049,957,156,840,000,000.00/yr
Blended yield
71.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AMIN
No analyst data
Altman Z
-6.4
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMIN buys
0
JNJ buys
0
No recent congressional trades found for AMIN or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMINJNJ
Forward yield500000.00% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28% ✓
Portfolio after 10y$252475121624236192.00M ✓$30.3K
Annual income after 10y$179,970,099,914,313,700,000,000.00 ✓$4,689.40
Total dividends collected$246974404501167104.00M ✓$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AMIN vs JNJ ($10,000, DRIP)

YearAMIN PortfolioAMIN Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$25,010,700$25,000,000.00$10,592$272.30+$25.00M → AMIN
2$29,244,868,926$29,218,107,476.64$11,289$357.73+$29244.86M → AMIN
3$15,996,042,711,578$15,964,750,701,827.40$12,123$472.89+$15996042.70M → AMIN
4$4,097,595,673,237,753$4,080,479,907,536,365.00$13,141$629.86+$4097595673.22M → AMIN
5$492,827,571,123,448,100$488,443,143,753,083,800.00$14,408$846.81+$492827571123.43M → AMIN
6$27,978,829,179,189,830,000$27,451,503,678,087,737,000.00$16,021$1,151.60+$27978829179189.81M → AMIN
7$758,198,099,371,876,500,000$728,260,752,150,143,400,000.00$18,122$1,588.22+$758198099371876.50M → AMIN
8$10,033,296,784,320,553,000,000$9,222,024,817,992,646,000,000.00$20,930$2,228.20+$10033296784320554.00M → AMIN
9$67,761,702,532,637,870,000,000$57,026,074,973,414,870,000,000.00$24,792$3,191.91+$67761702532637872.00M → AMIN
10$252,475,121,624,236,200,000,000$179,970,099,914,313,700,000,000.00$30,274$4,689.40+$252475121624236192.00M → AMIN

AMIN vs JNJ: Complete Analysis 2026

AMIN — Stock

American International Industries, Inc. holds interests in industrial, oil and gas, oilfield supply and service, and undeveloped real estate companies in the United States. The company supplies products to retailers and wholesalers in the automotive after-market and in the consumer durable electrical products markets under the Good Choice and MOTOR TREND brand names. Its MOTOR TREND branded products include booster cables, portable and rechargeable hand lamps, lighting products, cord sets, and miscellaneous battery and other consumer automotive accessories; and Good Choice branded products comprise portable lighting products, cord sets, residential household light bulbs, night lights, multiple outlet devices, and other consumer products. The company also provides owns oil and gas properties in Texas, as well as real estate holdings in Harris, Galveston, and Waller counties in Texas. American International Industries, Inc. was founded in 1994 and is based in Kemah, Texas.

Full AMIN Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AMIN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMIN vs SCHDAMIN vs JEPIAMIN vs OAMIN vs KOAMIN vs MAINAMIN vs ABBVAMIN vs MRKAMIN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.